GLP-1R agonists alleviate metabolic inflammation and NASH by suppressing the expression of inflammatory genes such as TNFα, IL-6, and nuclear factor NF-kappa-B (NFκB) (155, 156). This evidence concerns the gene IL6 and metabolic dysfunction-associated steatohepatitis.